BBS7

Across TCGA pan-cancer cohorts, BBS7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BBS7 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BBS7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BBS7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where BBS7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	22	view →
PDAC	OS	Median	IV	0.951	0.381	.006	16	view →
CCRCC	DFS	Median	III,IV	0.960	0.766	.013	10	view →
UCEC	OS	Quartile	III,IV	0.339	1.000	.027	4	view →
LUAD	OS	Tertile	II,III,IV	0.331	0.742	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BBS7–LSCC (DFS)

Open the LSCC breakdown →